Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized placebo-controlled study of mirabegron in pediatric overactive bladder
2016-001767-37Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron sequential dose titration with Placebo (2 arms). Primary endpoint: Mean number of micturitions per 24 hours. Started Jun 2020; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2016-001767-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001767-37.